After Cantor Fitzgerald and SunTrust Robinson gave Evolus Inc (NASDAQ: EOLS) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Irina Rivkind Koffler reiterated a Buy rating on Evolus Inc today and set a price target of $27. The company’s shares opened today at $19.79.
Rivkind Koffler wrote:
“We had modeled a $1M expense associated with a Canadian delay in 4Q:18, which can now come out of the model. The approval may create additional buzz in the physician community. We reiterate our Buy rating on EOLS and expect some pressure on AGN today.”
According to TipRanks.com, Koffler is a 5-star analyst with an average return of 11.7% and a 47.3% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Eagle Pharmaceuticals Inc, and Pacira Pharmaceuticals.
Currently, the analyst consensus on Evolus Inc is a Strong Buy with an average price target of $29.67, representing a 49.9% upside. In a report issued on August 2, Cantor Fitzgerald also maintained a Buy rating on the stock with a $35 price target.
.
See today’s analyst top recommended stocks >>
Based on Evolus Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $16.43 million. In comparison, last year the company had a GAAP net loss of $3.74 million.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EOLS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Evolus, Inc. is a medical aesthetics company. The company is engaged in providing physicians and patients with expanded choices in aesthetic procedures and treatments. Evolus was founded in November, 2012 and is headquartered in Irvine, CA.
